Seelos Therapeutics Inc (SEEL)

[Siforus]

Pre-Clinical Results Show NexACT(R) Technology Significantly Improves Subcutaneous Delivery and Anti-Metastatic Activity of Angstrom's A6 Cancer Compound

http://custom.marketwatch.com/custom/tdameritrade-com/html-story.asp?guid={9898FD2A-9F85-4465-B981-73DA733CA27E}

SAN DIEGO, Apr 28, 2010 (BUSINESS WIRE) -- NexMed, Inc. (NEXM), a specialty CRO with a pipeline of products based on the NexACT(R) technology, today announced that results from a pre-clinical study showed significant improvement in the delivery and half life of A6, a proprietary peptide treatment for ovarian cancer currently in Phase 2 development by Angstrom Pharmaceuticals. Specifically, the incorporation of NexACT(R) enabled the dose of A6 to be cut by half, or from twice per day to once per day delivered subcutaneously, while achieving the same level of efficacy in the mouse lung metastasis model.

Bassam Damaj, Ph.D., President and Chief Executive Officer of NexMed, stated, "These new findings, incorporating the NexACT-A6 peptide formulation, correlate with the half life and delivery profile of the A6 compound from Angstrom's previous studies using the higher dose. The positive results offer Angstrom the potential to clinically test the NexACT-A6 peptide at much higher doses while maintaining continuous coverage of the intended therapeutic target in human patients." Dr. Damaj further added, "This study was NexMed's first entry into the subcutaneous delivery of peptide drugs, and the results further confirmed the depot-like effect of the NexACT(R) technology which we had seen in our subcutaneous delivery studies with insulin and taxol."

Malcolm Finlayson, Ph.D., President and Chief Executive Officer of Angstrom noted, "Our relationship with NexMed continues to evolve in a fast and promising way. This new data is very exciting and warrants further investigation to support the opportunity to license the NexACT(R) technology for human clinical trials." About Angstrom Pharmaceuticals and A6 Based in San Diego, CA, Angstrom is developing a new class of drugs targeting CD44 for the treatment of diseases involving cell migration, invasion, and metastasis. Results from a completed Phase 1a safety clinical trial on A6 showed there were no systemic drug-related adverse events in healthy volunteers. Angstrom has also successfully completed a Phase 1b clinical trial evaluating A6 in women with advanced gynecologic cancer, and a Phase 2 clinical trial evaluating A6 in women with asymptomatic CA125 progression of epithelial ovarian cancer after first-line chemotherapy. Treatments were well tolerated and more than 40% of the patients dosed continuously with A6 experienced disease stabilization. For further information, go to .